
    
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The study
      will include the following sequential phases: Screening, Pre-Treatment (Cell Product
      Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up.
    
  